Denali Therapeutics, Inc. (DNLI)
20.71
-0.97
(-4.47%)
USD |
NASDAQ |
Apr 16, 16:00
20.86
+0.15
(+0.72%)
After-Hours: 04:53
Denali Therapeutics Cash from Investing (Quarterly) : 20.77M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | -52.90M |
| Protalix Biotherapeutics, Inc. | -1.112M |
| Biogen, Inc. | -1.232B |
| Agenus, Inc. | 0.78M |
| Curis, Inc. | 2.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -98.54M |
| Cash from Financing (Quarterly) | 192.13M |
| Free Cash Flow | -422.10M |
| Free Cash Flow Per Share (Quarterly) | -0.5703 |
| Free Cash Flow to Equity (Quarterly) | -97.95M |
| Free Cash Flow to Firm (Quarterly) | -100.06M |
| Free Cash Flow Yield | -11.81% |